As yesterday’s lead molecule enters today’s clinical trial, the standard operating script seems to call for product developers and clinicians to push away the originating basic scientists, lest their lofty impractical ideals disrupt a delicate balance of strategic compromise. Indeed many scientists may not understand the competing push and pull of efficacy versus toxicity and quality versus production costs.
The recent approval of the first liquid biopsy test for the diagnosis of non-small cell lung cancer (NSCLC) demonstrates how biomarker-based detection tools are becoming important components of precision medicine-based drug treatment regimes.
Modern drug discovery approaches take too long, are too expensive, have too many clinical failures and uncertain outcomes. There are many reasons for this unsustainable business model, but primarily, the approaches are not comprehensively holistic.
If we have learned anything from scientific research in the last 20 years, it is that finding cures to complex diseases is difficult. Despite the promise of the genomic revolution, disease progression and patient outcomes are still not easily predicted by genetic factors alone.
A growing number of oncology drugs are currently clinically available and more than a thousand compounds are being developed for oncology indications.
Interest in personalised medicine continues to grow, and epigenetic biomarkers are very informative in this respect, giving a clear indication of whether – and how – a patient’s gene expression profile has changed, as well as the rate of disease progression.
To meet the massive challenges of future healthcare, perhaps no two facets hold greater promise than biomarkers for precision medicine and systems biology for personalised patient care.
The progression from health to disease is marked by significant biological changes within an individual1. Clinically presenting symptoms, however, can be non-specific and variable enough to hinder diagnosis, and may appear only after a disease has already become well-established and consequently more difficult to treat.
A new collaborative research paper sheds light on the way antibodies distinguish between different but closely related ‘biomarkers’ – in this case protein fragments which reveal information about the condition of the human body. This new understanding could enable pharmaceutical companies to develop new technologies for quickly diagnosing and treating fatal diseases.
In a new whitepaper, experts at Oxford Gene Technology (OGT) discuss the issues surrounding the detection and utilisation of novel biomarkers for disease diagnosis.